TSTD1: The Potential Drug Target and Biomarker for Treating Syntopic Depression

Target Name: TSTD1

NCBI ID: G100131187

TSTD1

Other Name(s): putative thiosulfate sulfurtransferase KAT | Thiosulfate:glutathione sulfurtransferase | Thiosulfate:glutathione sulfurtransferase (isoform 1) | TSTD1 variant 2 | Thiosulfate sulfurtransferase like domain containing 1, transcript variant 2 | TSTD1 variant 3 | Thiosulfate sulfurtransferase like domain containing 1, transcript variant 3 | Thiosulfate sulfurtransferase like domain containing 1, transcript variant 1 | thiosulfate sulfurtransferase like domain containing 1 | TSTD1 variant 1 | Thiosulfate:glutathione sulfurtransferase (isoform 2) | Thiosulfate sulfurtransferase KAT, putative | thiosulfate sulfurtransferase/rhodanese-like domain-containing protein 1 | thiosulfate sulfurtransferase (rhodanese)-like domain containing 1 | TST | Putative thiosulfate sulfurtransferase KAT | Thiosulfate:glutathione sulfurtransferase (isoform 3) | KAT | Thiosulfate sulfurtransferase/rhodanese-like domain-containing protein 1 | TSTD1_HUMAN

TSTD1: The Potential Drug Target and Biomarker for Treating Syntopic Depression

Syntopic depression is a common condition that affects millions of individuals worldwide, characterized by persistent feelings of sadness, loss, and hopelessness. Despite the availability of various treatments, the symptoms of syntopic depression can remain uncontrolled or can even worsen, leading to a significant quality of life impairment. Therefore, there is a need for new and effective treatments to manage this debilitating condition.

TSTD1: A Potential Drug Target and Biomarker

TSTD1 (Tryptophan-TRNA synthase 1) is a gene that encodes a protein involved in the synthesis of tryptophan, a key amino acid that is essential for the structure and function of proteins. In the context of syntopic depression, TSTD1 has been found to be aberrantly expressed in the brains of individuals with syntopic depression. This increased expression of TSTD1 has been associated with increased levels of tryptophan in the brain, which may contribute to the persistent symptoms of syntopic depression.

Furthermore, previous studies have shown that individuals with syntopic depression have lower levels of brain-derived neurotrophic factor (BDNF), a protein that is involved in the maintenance and growth of brain cells. BDNF levels are known to be reduced in individuals with syntopic depression, and this reduction has been associated with increased neuron loss and reduced neuroplasticity. Therefore, TSTD1 may be a potential drug target for treating syntopic depression by increasing BDNF levels in the brain.

In addition to its potential role as a drug target, TSTD1 has also been identified as a potential biomarker for syntopic depression. The levels of TSTD1 have been found to be correlated with the levels of depressive symptoms, as measured by various standardized questionnaires. This suggests that TSTD1 may be a useful biomarker for identifying individuals at risk for syntopic depression and for monitoring the effectiveness of potential treatments.

The Identification of TSTD1 Interactions

While TSTD1 has been identified as a potential drug target and biomarker for syntopic depression, its function and interactions with other molecules are not well understood. Therefore, it is important to conduct further research to determine the precise role of TSTD1 in the treatment of syntopic depression.

One potential mechanism by which TSTD1 may contribute to the treatment of syntopic depression is by increasing the levels of neurotransmitters, such as serotonin and dopamine, in the brain. Individuals with syntopic depression have been shown to have lower levels of these neurotransmitters, and this may contribute to the persistent symptoms of syntopic depression. Therefore, increasing the levels of neurotransmitters by targeting TSTD1 may be a promising approach to treating syntopic depression.

Another potential mechanism by which TSTD1 may contribute to the treatment of syntopic depression is by modulating the activity of other genes involved in syntopic depression. For example, TSTD1 has been shown to be involved in the regulation of gene expression for genes involved in neurotransmitter synthesis, such as the serotonin transporter 5 (SERT5). Therefore, modulating the activity of these genes may be a promising approach to treating syntopic depression.

The Potential of TSTD1 as a Drug Target

The identification of TSTD1 as a potential drug target for syntopic depression provides a promising direction for future research. If TSTD1 can be successfully targeted, it may lead to the development of new and effective treatments for this debilitating condition.

The identification of TSTD1 as a potential drug target is based on several lines of evidence. Firstly, TSTD1 has been shown to be aberrantly expressed in the brains of individuals with syntopic depression. This increased expression of TSTD1 has been associated with increased levels of tryptophan in the brain, which may contribute to the persistent symptoms of syntopic depression. Secondly, TSTD1 has

Protein Name: Thiosulfate Sulfurtransferase Like Domain Containing 1

Functions: Thiosulfate:glutathione sulfurtransferase (TST) required to produce S-sulfanylglutathione (GSS(-)), a central intermediate in hydrogen sulfide metabolism (PubMed:24981631). Provides the link between the first step in mammalian H(2)S metabolism performed by the sulfide:quinone oxidoreductase (SQOR) which catalyzes the conversion of H(2)S to thiosulfate, and the sulfur dioxygenase (SDO) which uses GSS(-) as substrate (PubMed:24981631). The thermodynamic coupling of the irreversible SDO and reversible TST reactions provides a model for the physiologically relevant reaction with thiosulfate as the sulfane donor (PubMed:24981631)

The "TSTD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSTD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets